Moscony v. IDEXX Laboratories, Inc.

CourtDistrict Court, D. Connecticut
DecidedFebruary 6, 2024
Docket3:20-cv-00821
StatusUnknown

This text of Moscony v. IDEXX Laboratories, Inc. (Moscony v. IDEXX Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Moscony v. IDEXX Laboratories, Inc., (D. Conn. 2024).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT JODIE MOSCONY, ) Plaintiff, ) ) CASE NO. 3:20-cv-821 (OAW) v. ) ) IDEXX LABORATORIES, INC. and LIFE ) INSURANCE COMPANY OF NORTH ) AMERICA D/B/A CIGNA, ) Defendants. ) RULING ON DEFENDANTS’ MOTION FOR PARTIAL SUMMARY JUDGMENT THIS ACTION is before the court upon the Motion for Partial Summary Judgment filed by Defendants IDEXX Laboratories, Inc. (“IDEXX”) and Life Insurance Company of North America d/b/a CIGNA (“LINA”) (collectively, “Defendants”). ECF No. 129. Plaintiff Jodie Moscony suffers from hypersomnia, anxiety, and depression. While she was employed by IDEXX, she took a leave of absence. Shortly after her return, IDEXX terminated her. She alleges IDEXX negligently inflicted emotional distress on her during the termination process. She also alleges LINA, the third-party administrator for leaves of absence, aided and abetted IDEXX in violation of § 46a-60(b)(5) of the Connecticut Fair Employment Practices Act, Conn. Gen. Stat. § 46a-51 et seq. (“CFEPA”). Defendants move for summary judgment on these counts.1 The court has reviewed the motion, Plaintiff’s opposition, ECF No. 132, Defendants’ reply, ECF No. 139, and the record in this case. For the reasons discussed herein, the motion is GRANTED in part and DENIED in part.

1 Apart from these two claims, Plaintiff alleges IDEXX failed to accommodate her disabilities, unlawfully retaliated against her, and terminated her in violation of the CFEPA and the Americans with Disabilities Act, 42 U.S.C. §§ 12102 et seq. (“ADA”); and unlawfully retaliated against her in violation of the Family Medical Leave Act of 1993, 29 U.S.C. § 2611 et seq. (“FMLA”). Defendants do not move for summary judgment on these counts. The court therefore does not address evidence that concerns only these claims. I. BACKGROUND IDEXX is a company that develops, manufactures, and distributes products and services to veterinary clinics and hospitals. Pl.’s Local Rule 56(a)(2) Statement ¶ 1, ECF

No. 132-1 (“Pl.’s 56(a)(2) Stmt.”). For the relevant time period, LINA administered IDEXX’s FMLA, short-term disability, and long-term disability programs. Id. ¶ 5. According to IDEXX’s ADA Accommodations Guide, LINA also played a role in the ADA accommodations process insofar as it provided ADA request forms, collected ADA accommodations paperwork, and submitted the paperwork to the IDEXX Leave of Absence Program Manager. Pl.’s Ex. 88, ECF No. 132-36 at 10–12 (“ADA Guide”). From there, IDEXX was responsible for managing the accommodation request. Id. In June 2017, IDEXX hired Plaintiff as a Veterinary Diagnostic Consultant. Id. ¶ 2. In her role, Plaintiff was responsible for selling IDEXX’s products and developing customer relations. Id. ¶ 3. On May 7, 2018, Plaintiff disclosed her hypersomnia

diagnosis to her supervisor, Joseph Faiella. See Pl.’s Ex. 11, ECF No. 132-12 at 1–3 (“Moscony E-mail 5/7/18”). Three days after she disclosed her diagnosis, Plaintiff received a verbal warning for poor performance. Pl.’s Ex. 19, ECF No. 134-2 (“Sealed Verbal Warning 5/10/18”). Plaintiff submitted a reasonable accommodation request, which was granted in part on June 27, 2018. Pl.’s 56(a)(2) Stmt. ¶ 17. At the end of the summer, Plaintiff received a written warning for poor performance; this warning stated that she only averaged 16.1 calls per week but was expected to make 22 calls per week. Pl.’s Ex. 25, ECF No. 134-4 (“Sealed Written Warning 5/31/18”). (An Essential Job Functions Chart for Plaintiff’s position, dated June 8, 2018, does not mention an in-person sales call requirement. See Pl.’s Ex. 21, ECF No. 132-16 at 1–3 (“VDC II Essential Job Functions 6/8/18”).) Plaintiff took short term disability leave on September 11, 2018, and, once it ran out, remained out on FMLA leave. Pl.’s 56(a)(2) Stmt. ¶ 20. In December 2018, Plaintiff

completed LINA’s reasonable accommodation paperwork. Her health care provider, Charisse Litchman, M.D., submitted the requisite Fitness for Duty form, indicating Plaintiff could return to work December 20 with several restrictions. See Pl.’s 56(a)(2) Stmt. ¶ 22–24. In relevant part, Dr. Litchman opined that Plaintiff must be limited to no more than 10 to 15 in-person sales calls per week. See id. Plaintiff and IDEXX subsequently went through the ADA interactive process. Id. On December 21, IDEXX proposed alternative accommodations, including a gradual “ramp-up” to 20 to 25 weekly in-person sales calls over the course of several weeks. Id. ¶ 29. By mid-January 2019, Dr. Litchman clarified that Plaintiff patient could not return under IDEXX’s proposed conditions. Id. ¶¶ 31–33. LINA facilitated each side’s receipt of

the other’s communications. Id. ¶¶ 29–33. On February 11, 2019, Plaintiff’s new supervisor, Justin Van Deinse, sent Plaintiff an e-mail with two proposed options for accommodations, both with different “ramp-up” schedules that required Plaintiff to make 20 to 25 weekly in-person sales calls by Monday, February 25, 2019. Id. ¶ 36. One option required Plaintiff to return to work on Tuesday, February 12 and do administrative work the remainder of that week, to perform 10 to 20 in-person sales calls the second week, and to perform 20 to 25 in-person sales calls the third week. Pl.’s Ex. 57, ECF No. 132-27 at 1–2 (“Van Deinse E-mail 2/11/19”). The second option contemplated a return date of Wednesday, February 20 with full territory coverage that week. Id. In this e-mail, Van Deinse informed Plaintiff that IDEXX would begin its search for her replacement if she did not make 20 to 25 sales calls by February 25. Id. After some e-mail exchange and with IDEXX’s resulting permission, Plaintiff was approved to return to work on Monday, February 18. Id. ¶ 39; Pl.’s Ex. 34, ECF No. 132-

21 at 9–14 (“Blanchard E-mail 12/19/18”) (prohibiting return until fitness for duty form is complete); Pl.’s Ex. 58, ECF No. 132-27 (“Van Deinse E-mail 2/13/19”) (permitting return to work on 2/18/19). Plaintiff visited Dr. Litchman’s office on February 20, 2019. See Pl.’s Ex. 67, ECF No. 134-13 at 7–9 (“Sealed Second Moscony E-mail 2/25/19”). Dr. Litchman wrote a letter that day specifying Plaintiff required a three-week in-office ramp up period and a restriction of 10 to 15 in-person visits per week. See id. On February 25, 2019, at 3:04 PM, Douglas Perry, the Senior Area Sales Director for the East, sent Plaintiff an updated written warning (revising the August 2018 written warning). See Pl.’s Ex. 62, ECF No. 134-12 (“Sealed Written Warning, Revised 2/15/19”).

Shortly after 5:00 PM, Plaintiff sent IDEXX two e-mails. In the first e-mail (sent 5:14 PM), Plaintiff informed Rebecca Blanchard of Human Resources that she believed IDEXX was subjecting her to discrimination, harassment, and retaliation on the basis of her disability. See Pl.’s Ex. 63, ECF No. 132-29 (“First Moscony E-mail 2/25/19”). She also explained that she had a call earlier that day with Perry and Van Deinse in which they told her they “have been actively recruiting for [her] replacement….” Id. In the second e-mail (sent 5:32 PM), Plaintiff sent Sean Siebert, Leave of Absence Program Manager, a new accommodation request, attaching Dr. Litchman’s February 20 letter. See Sealed Second Moscony E-mail 2/25/19. Van Deinse e-mailed Plaintiff a memorandum on March 4, 2019. Pl.’s 56(a)(2) Stmt. ¶ 48. IDEXX approved some of the accommodation requests but remained firm that it would not approve 10 to 15 weekly in-person sales calls on the grounds it was “not a reasonable accommodation given that it is an essential function to have 20-25 face to

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Vivenzio v. City of Syracuse
611 F.3d 98 (Second Circuit, 2010)
Brown v. Eli Lilly and Co.
654 F.3d 347 (Second Circuit, 2011)
Redd v. New York Division of Parole
678 F.3d 166 (Second Circuit, 2012)
Belanger v. Commerce Clearing House, Inc.
25 F. Supp. 2d 83 (D. Connecticut, 1998)
Edwards v. Community Enterprises, Inc.
251 F. Supp. 2d 1089 (D. Connecticut, 2003)
Bolick v. Alea Group Holdings, Ltd.
278 F. Supp. 2d 278 (D. Connecticut, 2003)
Chen v. Pitney Bowes Corp.
195 F. Supp. 2d 368 (D. Connecticut, 2002)
Leach v. F.A. Bartlett Tree Expert Co.
112 F. Supp. 2d 230 (D. Connecticut, 2000)
Tyszka v. Edward McMahon Agency
188 F. Supp. 2d 186 (D. Connecticut, 2001)
Copeland v. Home & Community Health Services, Inc.
285 F. Supp. 2d 144 (D. Connecticut, 2003)
Fletcher v. Atex, Inc.
68 F.3d 1451 (Second Circuit, 1995)
Morris v. Hartford Courant Co.
513 A.2d 66 (Supreme Court of Connecticut, 1986)
Perodeau v. City of Hartford
792 A.2d 752 (Supreme Court of Connecticut, 2002)
Carrol v. Allstate Insurance
815 A.2d 119 (Supreme Court of Connecticut, 2003)
Grasso v. Connecticut Hospice, Inc.
54 A.3d 221 (Connecticut Appellate Court, 2012)
Robinson v. Concentra Health Services, Inc.
781 F.3d 42 (Second Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Moscony v. IDEXX Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/moscony-v-idexx-laboratories-inc-ctd-2024.